BioSpace News Archive

Policy

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In OPKO Health, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in OPKO Health, Inc. (“OPKO” or the “Company”) (NASDAQ: OPK) of the November 13, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company

September 17, 2018
·
2 min read
BioForest

40+ Healthcare Organizations Launch Unprecedented Effort to Improve Accuracy and Timeliness of Diagnosis

Every nine minutes, someone in a U.S. hospital dies due to a medical diagnosis that was wrong or delayed

September 17, 2018
·
8 min read
Pharm Country

63% of Business Leaders Lack Required Ability to Achieve Success

Flaum Navigators Offers Top 6 Business Tips

September 17, 2018
·
2 min read
Policy

FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Disease

Designation enhances FDA orphan drug designation for Phase I candidate targeting incurable blindness in children.

September 17, 2018
·
2 min read
Pharm Country

PatientPoint Named Vendor/Supplier Company of the Year by PM360 Magazine

PatientPoint® has been named 2018 Gold Supplier/Vendor Company of the Year by PM360 magazine, a leading publication for marketers in the pharmaceutical, biotech and medical device industries.

September 17, 2018
·
3 min read
Biotech Beach

Retrophin Recognizes Rare Disease Day® 2018 and Joins Others Worldwide to Raise Awareness About Rare Diseases

Retrophin, Inc. (NASDAQ: RTRX) today joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and rare disease advocates and patients worldwide to recognize Rare Disease Day® 2018.

September 17, 2018
·
4 min read
Business

Retrophin Reports Fourth Quarter and Full Year 2017 Financial Results

Retrophin, Inc. (NASDAQ:RTRX) today reported its fourth quarter and full year 2017 financial results and provided a corporate update.

September 17, 2018
·
18 min read
Business

Retrophin Announces Appointment of Casey Logan as Vice President of Corporate Development

Retrophin, Inc. (NASDAQ:RTRX) today announced that Casey Logan has joined the Company as vice president, corporate development.

September 17, 2018
·
3 min read
Drug Development

Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis

Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been enrolled in the DUPLEX Study, a global, pivotal Phase 3 clinical trial.

September 17, 2018
·
8 min read
Business

Retrophin Reports First Quarter 2018 Financial Results

Retrophin, Inc. (NASDAQ:RTRX) today reported its first quarter 2018 financial results and provided a corporate update.

September 17, 2018
·
16 min read